The global Anti-Viral Drugs Market is expected to be valued at US$ 59,596.8 Million in 2022. The induction of the generic version of antiviral medicines and rising awareness about the availability of various vaccines for viral infections is affecting the growth throughout the forecast period. The overall demand for Anti-Viral Drugs is projected to grow at a CAGR of 3.9% between 2022 and 2032, totalling around US$ 87,675.36 Million by 2032.
Anti-viral drugs are medicines which are used specially for treating viral infections. Most anti-viral drugs are used for particular viral infections, similar to antibiotics, while a broad-spectrum anti-viral drug is effective against a varied range of viruses. Antiviral drugs do not kill their target pathogen, instead they inhibit the development of those viruses.
The global anti-viral drugs market is projected to register a moderate growth rate in the pharmaceutical market and which is anticipated to increase due to rise in awareness level, increase in the diseased population and introduction of new drugs with improved efficacy.
Some major patents are reaching their expiry during forecast period, such as for Combivir, Sustiva, Tenofovir, Tamiflu, Relenza and Telbivudine. The patent expiries of these blockbuster drugs is expected to trigger generic competition in the antivirals therapeutics market, which will make the market more competitive.
The late stage pipeline drugs are expected to enter the market, which will positively impact the market. Most antivirals are considered comparatively harmless to host, and therefore are used to treat infections. They are different from viricides, which are not used for medication but can destroy or deactivate virus particles, either outside or inside the body.
The anti-viral drugs are used in the treatment of patients suffering from herpes viruses, HIV, influenza A and B viruses and the hepatitis B and C viruses.
Anti-viral Drugs Market: Overview
The generic market of anti-viral drugs is presently dominated by products such as didanosine, zidovudine, lamivudine and stavudine. The biggest driver of overall anti-viral drugs market is Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) therapeutic sales which accounted for more than half the share of the market 2010.
At the end of 2012, 9.7 million people in low-income and middle-income countries were on antiretroviral treatment (ART). According to WHO, in 2012, number of patients on ART increased by 1.6 Mn, the largest increase in one year.
Nearly four out of five people were freshly put on treatment in the sub-Saharan Africa. In 21 African countries with a high burden of HIV, two out of three people in need are receiving treatment, and two out of three positive pregnant women are receiving antiretroviral drugs to prevent HIV transmission to their infants.
Anti-viral Drugs Market: Key Players
Some of the key players in global anti-viral drugs market, which are focusing on general molecular mechanisms of antiviral drugs rather than therapies for individual viruses, include Roche, Gilead, GlaxoSmithKline, Bristol-Myers-Squibb, Abbott, AstraZeneca, Cipla, Schering-Plough, Johnson & Johnson, Merck & Co and others.
Browse More Details@ https://www.futuremarketinsights.com/reports/anti-viral-drugs-market
The global anti-viral drugs market is driven by rise in healthcare expenditure and emergence of life-threatening diseases.
These factors have helped shape the anti-viral drugs market and are expected to boost the growth.
Anti-viral drugs market analysts have also shared growth projections in the report and have suggested anti-viral drugs market players to plan growth strategies accordingly.Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/2454SegmentationThe global anti-viral drugs market has been segmented based on application and mechanism of action.
By application, the market has been segmented into hepatitis, HIV/AIDS, herpes, influenza and others.
Growing prevalence of viral infections in the region, the presence of key players in the region and high healthcare expenditure drives the market in the Americas.
The Europe market is driven by the presence of a robust healthcare sector and high investment in R activities.
Marketresearchfuture.com has published new research report on “Global Anti-viral drugs Market Research Report Global Forecast till 2022” to its database.Anti-viral drugs Market OverviewThe global anti-viral drugs market is expected to grow at a CAGR of 6.9% and attain USD 62.67 Bn by the end of the forecast period of 2016-2022, asserts Market Research Future (MRFR) in an exhaustive research report.
Infectious diseases such as influenza, herpes, hepatitis C are among the leading causes of death worldwide.
The paucity of new anti-viral drugs will be addressed by this drug development which will eliminate the reliance on the limited number of drugs.
Besides, growing focus on R activities provides ample opportunities for market growth.
Other factors impeding the growth of the market include the high cost of drug development and loss of patent of various drugs.
However, loss of patent of drugs has provided growth opportunities for generics which will drive the market in the coming years.
